PDE III inhibitors for treatment of asymptomatic heart failure
Phosphodiesterase type III (PDE III) inhibitor or a “Ca 2+ -sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
1. An article of manufacture including:
packaging material; and
at least one pharmaceutical composition contained in the packaging material, the at least one pharmaceutical composition comprising:
a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor comprising pimobendan, wherein said therapeutically effective amount is effective to prolong time until onset of clinical symptoms of heart disease and/or to reduce heart size for a patient having ISACHC (International Small Animal Cardiac Health Council) Class I heart failure; and
a second active therapeutic agent consisting of at least three of benazepril, enalapril, spironolactone, and furosemide.
2. The article according to claim 1 , wherein the PDE III inhibitor further comprises at least one of milrinone, levosimendan, amrinone, enoximone, piroximone, and pharmaceutically acceptable salts thereof.
3. The article according to claim 2 , wherein the PDE III inhibitor further comprises levosimendan.
4. The article according to claim 1 further comprising a label indicating that the at least one pharmaceutical composition can be used to prolong the time until onset of symptoms and to reduce heart size of a patient having ISACHC (International Small Animal Cardiac Health Council) Class I heart failure.
5. The article according to claim 1 , wherein the reduction of the heart size is expressed in the relative change of the vertebral heart size.
6. The article according to claim 1 , wherein the ISACHC (International Small Animal Cardiac Health Council) Class I heart failure is asymptomatic dilated cardiomyopathy (DCM).
7. The article according to claim 1 , wherein prolongation until onset of clinical symptoms relates to the time from diagnosing the changes of the heart until the beginning of clinical symptoms of ISACHC (International Small Animal Cardiac Health Council) Class II or Class III heart failure.
8. The pharmaceutical composition according to claim 1 , wherein the second active therapeutic agent consists of:
benazepril, spironolactone, and furosemide; or
enalapril, spironolactone, and furosemide.
9. A pharmaceutical composition comprising:
a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor comprising pimobendan, wherein said therapeutically effective amount is effective to prolong time until onset of clinical symptoms of heart disease and/or to reduce heart size for a patient having ISACHC (International Small Animal Cardiac Health Council) Class I heart failure; and
a second active therapeutic agent consisting of at least three of benazepril, enalapril, spironolactone, and furosemide;
wherein the pharmaceutical composition includes the PDE III inhibitor and the second active therapeutic agent within a single dosage unit.
10. The pharmaceutical composition according to claim 9 , wherein the PDE III inhibitor further comprises at least one of milrinone, levosimendan, amrinone, enoximone, piroximone, and pharmaceutically acceptable salts thereof.
11. The pharmaceutical composition according to claim 10 , wherein the PDE III inhibitor further comprises levosimendan.
12. The pharmaceutical composition according to claim 9 , wherein the ISACHC (International Small Animal Cardiac Health Council) Class I heart failure is asymptomatic dilated cardiomyopathy (DCM).
13. The pharmaceutical composition according to claim 9 , wherein the pharmaceutical composition is in the form of a liquid.
14. The pharmaceutical composition according to claim 9 , wherein the pharmaceutical composition is in the form of a tablet and one or both of the pimobendan and the second pharmaceutical active agent is enteric coated within the tablet.
15. The pharmaceutical composition according to claim 9 , wherein the second active therapeutic agent consists of:
benazepril, spironolactone, and furosemide; or
enalapril, spironolactone, and furosemide.